Advertisement
week in cancer news
  • June 23: The Week in Cancer News

    New treatments have changed care for multiple myeloma, and as drug companies have moved away from producing generics, the U.S. runs into cancer drug shortages.

    by Eric Fitzsimmons

  • June 16: The Week in Cancer News

    Women diagnosed with early-stage breast cancer are more likely to live five years or longer compared with those diagnosed in earlier decades, and reports of functional limitations increase among cancer survivors.

    by Marci A. Landsmann

  • June 9: The Week in Cancer News

    Daily pill lowers lung cancer death rate, and FDA authorizes importing shortage-affected cancer drugs from China.

    by Kevin McLaughlin

  • June 2: The Week in Cancer News

    Minimally invasive surgery found to be effective for pancreatic cancer patients, and drug shortages begin to impact some cancer treatments.

    by Thomas Celona

  • May 26: The Week in Cancer News

    High cancer death rates in Native Hawaiian and Pacific Islander communities, and thousands of people lose Medicaid for procedural reasons.

    by Eric Fitzsimmons

  • May 19: The Week in Cancer News

    Cancer drugs are affected by shortages, and angiogenesis inhibitors make a comeback in combination treatments.

    by Kevin McLaughlin

  • May 12: The Week in Cancer News

    Mammography screening recommendation pushed back to age 40, and pancreatic cancer vaccine shows promising immune response.

    by Marci A. Landsmann

  • May 5: The Week in Cancer News

    Researchers discover a new way breast density can impact cancer risk, and CAR T-cell therapy remains out of reach for patients with HIV.

    by Thomas Celona

  • April 28: The Week in Cancer News

    More programs address sexual health in cancer survivors, and survey suggests health insurance often doesn’t cover genetic tumor testing.

    by Marci A. Landsmann

  • April 21: The Week in Cancer News

    Awareness of HPV link to cancer has declined, and more frequent COVID-19 boosters authorized for people who are immunocompromised.

    by Eric Fitzsimmons